Evommune (NYSE:EVMN) CFO Sells $415,117.00 in Stock

Evommune, Inc. (NYSE:EVMN) CFO Kyle Carver sold 18,175 shares of Evommune stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $22.84, for a total value of $415,117.00. Following the completion of the sale, the chief financial officer owned 59,335 shares in the company, valued at approximately $1,355,211.40. The trade was a 23.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Evommune Trading Down 0.2%

EVMN stock opened at $19.78 on Thursday. Evommune, Inc. has a 12-month low of $13.89 and a 12-month high of $33.20. The firm has a market cap of $712.62 million and a PE ratio of -2.08. The business has a 50-day moving average price of $23.98.

Evommune (NYSE:EVMN) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.19. As a group, equities research analysts anticipate that Evommune, Inc. will post -2.83 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on EVMN. Evercore restated an “outperform” rating and set a $55.00 target price on shares of Evommune in a report on Tuesday, February 10th. Morgan Stanley boosted their target price on Evommune from $54.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Stifel Nicolaus began coverage on Evommune in a report on Friday, May 1st. They set a “buy” rating and a $54.00 target price on the stock. Wall Street Zen upgraded Evommune from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. Finally, Oppenheimer began coverage on Evommune in a report on Tuesday, April 7th. They set an “outperform” rating and a $50.00 target price on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Evommune presently has a consensus rating of “Buy” and a consensus price target of $49.25.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. purchased a new position in Evommune in the fourth quarter worth approximately $34,000. Strs Ohio purchased a new position in Evommune in the first quarter worth approximately $41,000. The Manufacturers Life Insurance Company purchased a new position in Evommune in the fourth quarter worth approximately $179,000. XTX Topco Ltd purchased a new position in Evommune in the fourth quarter worth approximately $321,000. Finally, Oxford Asset Management LLP purchased a new position in Evommune in the fourth quarter worth approximately $335,000.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.